Effectiveness of nebulized gentamicin as an adjunctive treatment of ventilator-associated and hospital-acquired pneumonia in mechanically ventilated patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202512777613976

Enrollment

Registered

2025-12-09

Start date

2024-10-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventilator-associated pneumonia and Hospital-acquired pneumonia Respiratory

Interventions

Gentamicin

normal saline

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Mechanically ventilated patients Aged 18 years or more Pneumonia either VAP or HAP (defined as the presence of a new or progressive infiltrate(s) on chest radiograph and at least two of the following signs: fever, defined as core temperature >38.0°C or hypothermia, core temperature <35.0°C leukocyte count =11,000/mm3 or =4,500/mm3 new onset of purulent sputum production or respiratory secretions, or a change of sputum characteristics)

Exclusion criteria

Exclusion criteria: History of primary lung cancer or another malignancy metastasized to the lung Known or suspected active tuberculosis, cystic fibrosis, AIDS. Have received gentamicin within the preceding seven days Previously documented intolerance or allergy to inhaled aminoglycoside

Design outcomes

Primary

Measure	Time frame
Resolution of signs of infection or obtaining culture-negative in culture-positive patients	—

Secondary

Measure	Time frame
Length of mechanical ventilation Length of ICU stay ;Oxygenation parameters Adverse effects ;ICU mortality rate	—

Countries

Egypt

Contacts

Public ContactMaha Atta

Researcher

mahaatta90@hotmail.com+201279111076

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026